The Clinical Analysis Of 121 Patients With Intermediate And Advanced Gastric Cancer Received Chemotherapy

OBJECTIVETo explore the effectiveness and safety of SOX regimen versus DCF regimen in the treatment of patients with intermediate and advanced gastric cancer. The rationality and the quantitation of the chemotherapy was discussed.METHODSThe 121 intermediate and advanced gastric cancer patients were retrospectively analyzed in the Affiliated Cancer Hospital of Guangxi Medical University from March,2010 to March,2014.They were received SOX regimen or DCF regimen. The objective efficiency was evaluated according to RECIST 1.1 criteria. The complete respond(CR),partial respond(PR), stable disease(SD), progressive disease(PD), reponse rate(RR) and disease control rate (DCR) were observed. Toxicities were evaluated according to NCI-CTC 4.0.RESULT74 cases of which were received DCF regimen and all can be firstly evaluated for effectiveness and adverse reaction. The CR, PR, SD, PD was 1 cases,21cases,44 cases and 8 cases respectively. The RR and DCR were 29.7% and 89.2%.28 cases of the 74 cases sequentially received DCF regimen after that.28 cases can be secondly evaluated for effectiveness and adverse reaction. The CR, PR, SD, PD was 1 cases,2 cases,21 cases and 4 cases respectively. The RR and DCR were 10.7% and 85.7%. DCF regimen was effective when firstly evaluated and needed 2 to 3 cycles(2.29± 0.72).47 cases of which were received SOX regimen and all can be firstly evaluated for effectiveness and adverse reaction. The CR, PR, SD, PD was 2 cases,20 cases,20 cases and 5 cases respectively. The RR and DCR were 46.8% and 89.4%.17 cases of the 47 cases sequentially received SOX regimen after that.17 cases can be secondly evaluated for effectiveness and adverse reaction. The CR, PR, SD, PD was 1 cases,2 cases,10 cases and 2 cases respectively. The RR and DCR were 17.6% and 76.5%. The SOX regimen was effective when firstly evaluated and needed 2 to 3 cycles(2.35± 0.81).CONCLUSION1.It is about 3 cycles effectively for the intermediate and advanced gastric cancer patients who received the same regimen. It is worth discussing whether to change the regimen or change other treatments after the same regimen for 3 cycles.2.It may take the greatest benefit for the patients who received sequential chemotherapy at the right time when the RR or DCR is lower than the critical value.